The hypoxia-activated prodrug carbonic anhydrase IX inhibitors (HAP-CAIs) reported here were assayed using the CO2 hydrase assay against three physiologically relevant human CA isoforms, the cytosolic hCA I and II and the transmembrane, tumor-associated hCA IX (Table 1) [32]. Here, CA9 is linked to neoplasm.